B

BeOne

Global oncology therapeutics discovery, development, manufacturing

Executive Research Sourcer Contract

Full-TimeUpdated on 10/23/2026Deadline 12/1/26
No salary listed
Expert
Bachelor's
Remote in USA
RemoteRemote within the United States; flexible working hours with the APAC team.
People & HRTechnical Recruiting

About the job

Requirements
  • Fluency in Mandarin and English is required.
  • Flexible working hours are required to work with the APAC team.
  • At least 10 years of Talent Acquisition experience is required, including at least 5 years of experience in Executive Search, talent sourcing, talent intelligence, or specialized scientific recruiting.
  • A proven ability to identify and engage passive candidates for highly specialized or leadership-level positions is required.
  • Experience supporting Biotechnology, Pharmaceutical, Life Sciences, Research, or Innovation-focused organizations is required.
  • Expertise in talent mapping, organizational research, competitive intelligence, and market analysis is required.
  • Strong sourcing capability using LinkedIn Recruiter and other research platforms is required.
  • Stakeholder management, consulting, and influencing skills are required.
  • An analytical mindset and the ability to translate market intelligence into actionable business insights are required.
Responsibilities
  • Lead talent scouting initiatives for critical Research positions, focusing on senior and highly specialized scientific talent.
  • Develop targeted sourcing strategies across academia, biotechnology companies, pharmaceutical organizations, research institutes, and innovation ecosystems.
  • Partner with Recruiters, Hiring Managers, HRBPs, and Research leaders to understand strategic talent requirements and develop proactive talent plans.
  • Identify and engage passive candidates through innovative sourcing approaches and relationship-driven outreach.
  • Build talent pipelines for immediate hiring needs and future organizational growth.
  • Develop talent attraction strategies for highly competitive and business-critical positions.
  • Conduct talent mapping and competitive talent landscape analysis across therapeutic areas, research platforms, scientific disciplines, and target organizations.
  • Track industry trends, scientific talent movements, organizational developments, and emerging areas of expertise.
  • Deliver actionable market intelligence on talent availability, organization structures, talent density, and competitive talent landscapes.
  • Support workforce planning and strategic growth discussions through data-driven talent insights.
  • Advise on market dynamics and talent trends impacting Research organizations.
  • Build and expand strategic talent networks across the global scientific community.
  • Identify and engage established and emerging scientific leaders through industry conferences, professional forums, academic partnerships, and innovation ecosystems.
  • Develop relationships through healthcare industry events including the JP Morgan Healthcare Conference, scientific congresses and professional research forums, leading academic institutions and research organizations, professional scientific associations and societies, and biotechnology and pharmaceutical innovation hubs.
  • Use scientific publications, patents, conference presentations, and industry recognition to identify high-potential talent.
  • Strengthen BeOne’s visibility and employer reputation within the scientific community through ongoing talent engagement and relationship building.
  • Build and maintain long-term relationships with distinguished scientists, research leaders, and emerging scientific talent globally.
  • Develop targeted talent communities aligned with priority therapeutic areas, research platforms, and future pipeline needs.
  • Manage and continuously enrich strategic Research talent databases and talent networks.
  • Maintain proactive engagement through scientific events, publications, professional forums, and personalized outreach.
  • Track talent movement, scientific achievements, publications, patents, leadership progression, and organizational changes to anticipate future hiring opportunities.
  • Transform talent databases into active, sustainable talent pipelines supporting long-term workforce needs.
  • Use advanced sourcing methodologies, talent intelligence tools, scientific research resources, publications, conferences, professional networks, and referral channels.
  • Leverage AI-enabled sourcing technologies and market research tools to improve sourcing effectiveness and scalability.
  • Optimize talent discovery strategies through data insights and market feedback.
  • Share market intelligence and sourcing best practices across the Talent Acquisition organization.
  • Contribute to the evolution of a Research Talent Scouting capability supporting BeOne’s long-term innovation agenda.
Desired Qualifications
  • A degree in Life Sciences, Biology, Biotechnology, Pharmacy, Chemistry, Medicine, or a related scientific discipline.
  • Experience supporting executive-level or highly specialized Research hiring.
  • Prior experience conducting strategic talent intelligence and workforce planning projects.
  • Familiarity with talent intelligence and sourcing platforms such as LinkedIn Talent Insights, SeekOut, HireEZ, Talent Neuron, GEM, or similar solutions.
  • A strong understanding of the global scientific talent landscape and research ecosystem.

About the company

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 25, 2026 FDA approval expanded TEVIMBRA in first-line HER2-positive gastroesophageal cancer.
  • August 31, 2026 Phase 3 survival data strengthened ZIIHERA-containing regimens.
  • Q2 2026 revenue hit $1.7 billion; management raised 2026 guidance to $6.8 billion.

What critics are saying

  • BeOne accepted developed-market pricing parity and Medicaid rebates on future U.S. approvals.
  • Zydus' BRUKINSA ANDA lawsuit targets patents; a 2034 composition patent remains the fortress.
  • AbbVie's trade-secrets case over BGB-16673 still threatens the BTK-degrader franchise.

What makes BeOne unique

  • BeOne built 35-plus assets and 93 trials across 1,100 U.S. sites by September 2026.
  • BRUKINSA dominates revenue, with 2026 global sales above $1.2 billion quarterly.
  • Hopewell, New Jersey gives BeOne U.S. manufacturing, R&D, and packaging capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • 401(k) Retirement Plan
  • Wellness Program
  • Paid Vacation

Growth & Insights and Company News

6 month growth

8%

1 year growth

-6%

2 year growth

-1%
Associated Press
Oct 6th, 2026
Onco360 partners with BeOne Medicines to distribute Beqalzi for relapsed mantle cell lymphoma

Onco360, an independent specialty pharmacy, has been selected as a pharmacy partner by BeOne Medicines for Beqalzi (sonrotoclax). The drug is indicated for treating adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor. Beqalzi is a BCL-2 protein inhibitor. In a Phase 1/2 study of 103 adult patients with relapsed/refractory mantle cell lymphoma, the drug achieved an overall response rate of 52.4%, with a median time to response of 1.9 months. The median duration of response was 15.8 months. Onco360 is headquartered in Louisville, Kentucky, and operates as a flagship brand of PharMerica Corporation.

Yahoo Finance
Sep 4th, 2026
BeOne secures US pharma-tariff exemption after $1B+ manufacturing investment, but pricing concessions raise margin concerns

BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs through a voluntary agreement with the US government. The deal recognises over $1 billion in US manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption protects BeOne from import duties on patented pharmaceuticals and ingredients. However, the company committed to pricing future FDA-approved medicines in line with other developed markets and participating in the Medicaid GENEROUS Model, which uses supplemental rebates. The Hopewell expansion will add small-molecule manufacturing and packaging capacity, creating approximately 120 full-time jobs. The facility will support a portfolio of more than 35 assets. Whilst the tariff exemption reduces supply-chain risk, international reference pricing commitments could limit pricing flexibility for future oncology medicines. Neither the tariff savings nor the financial impact of pricing concessions was disclosed.

Yahoo Finance
Aug 13th, 2026
Revolution Medicines shares rise 6.2% on BeOne-funded Phase 3 RAS(ON) deal

Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.

Yahoo Finance
Aug 5th, 2026
BeOne Medicines Q2 revenue up 30% to $1.7B as BRUKINSA sales top $1.2B globally

BeOne Medicines reported second-quarter revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS rising 144% to $2.05. The company's BTK inhibitor BRUKINSA generated more than $1.2 billion in global sales, increasing 31% from the prior year. The company raised its 2026 revenue guidance to CNY 6.6 billion–CNY 6.8 billion and expects GAAP operating income of CNY 1 billion–CNY 1.1 billion. Free cash flow doubled year over year to CNY 435 million. BeOne received FDA approval for Beqalzi in relapsed or refractory mantle cell lymphoma and reported positive Phase III results for a chemotherapy-free BRUKINSA regimen. US BRUKINSA sales totalled $893 million, up 31%, driven by demand in chronic lymphocytic leukaemia and non-CLL indications.

Yahoo Finance
Jul 23rd, 2026
BeOne CEO sells $34.6M in stock while retaining 50M+ shares

John Oyler, chief executive officer of BeOne Medicines AG, sold 109,713 American Depositary Shares worth $34.6 million on 20 and 21 July 2026, according to SEC filings. The transactions were executed under a Rule 10b5-1 trading plan adopted in March 2026. Despite the sale, Oyler retains a substantial ownership position exceeding 50.4 million total shares through various holdings. These include 28.2 million shares held through Oyler Investment LLC and 9.5 million shares in a Roth IRA account. The shares were sold at a weighted average price of $315.28. BeOne Medicines is a commercial-stage oncology biopharmaceutical company with $5.7 billion in trailing twelve-month revenue and a market capitalisation of $34.2 billion.